PharmaMar deal adds late-stage asset to Jazz’s growing cancer pipeline

Jazz’s deal to gain exclusive, U.S. rights to PharmaMar’s Zepsyre marks the company’s third cancer partnership of the year, adding a late-stage asset in small cell lung cancer as it continues to expand its pipeline beyond its flagship narcolepsy programs.


Read the full 413 word article

How to gain access

Continue reading with a
two-week free trial.